OPTPRESS Trial Analysis
I cannot provide an analysis of the OPTPRESS (Optimization of Pressure) trial because this trial does not appear in the provided evidence base. The evidence provided contains references to multiple hypertension trials including STOP-Hypertension-2, HOT (Hypertension Optimal Treatment), INVEST, VALUE, ACCORD BP, TOHP, ABCD, and UKPDS, but no OPTPRESS trial is mentioned or analyzed 1.
What the Evidence Does Show
The provided studies focus on different aspects of blood pressure management:
Trials in Normotensive/Prehypertensive Patients with CVD
Among patients with cardiovascular disease but without hypertension (BP <140/90 mmHg), antihypertensive treatment significantly reduces major cardiovascular events and mortality 1. The meta-analysis demonstrated:
- Stroke reduction: 7.7 fewer events per 1000 persons treated 1
- Heart failure reduction: 43.6 fewer events per 1000 persons treated 1
- Composite CVD events reduction: 27.1 fewer events per 1000 persons treated 1
- All-cause mortality reduction: 13.7 fewer deaths per 1000 persons treated 1
Optimal Blood Pressure Targets
The HOT study established that for diabetic patients, lowering diastolic BP below 80 mmHg decreases major cardiovascular events compared to targets <90 mmHg 2. For the general hypertensive population, the lowest cardiovascular event rate occurred at diastolic BP of 83 mmHg 2.
Treatment Approaches in Established Hypertension
European guidelines recommend achieving BP <140/90 mmHg minimum in all hypertensive patients, with lower targets of <130/80 mmHg for diabetics and high-risk patients with established cardiovascular disease 1.
Common Pitfall
Confusing trial names or requesting analysis of studies not included in the evidence base can lead to inaccurate clinical decision-making. If you are seeking information about a specific trial, verify the exact trial name and ensure relevant evidence is available.